ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BMY Bristol Myers Squibb Co

43.99
0.29 (0.66%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bristol Myers Squibb Co NYSE:BMY NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.29 0.66% 43.99 44.33 43.685 43.93 12,104,157 01:00:00

Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnost...

07/08/2014 4:00pm

PR Newswire (US)


Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Bristol Myers Squibb Charts.

NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ --

  • Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics
  • Leica Biosystems will develop fully automated tissue-based companion diagnostic tests to run on the BOND™ automated advanced staining systems

Leica Biosystems, today announced an agreement with Bristol-Myers Squibb Company (NYSE: BMY) to collaborate on developing companion diagnostics on the Leica BOND system for use as an aid in selecting patients for treatment with certain pharmaceuticals developed, or to be developed, by Bristol-Myers Squibb. Other terms of the agreement were not disclosed.

"We are pleased to be working with Bristol-Myers Squibb, on diagnostics for cancer and other therapies on the Leica BOND platform," added Matthias Weber, President of Leica Biosystems, MD. "This partnership is an example of Leica's continued growth in Companion Diagnostics. In this field the capabilities to supply high quality In Vitro Diagnostic products are critical requirements. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests."

About Leica Biosystems  

Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients' lives. Leica Biosystems provides anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica's easy-to-use and reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in seven countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at LeicaBiosystems.com.

SOURCE Leica Biosystems

Copyright 2014 PR Newswire

1 Year Bristol Myers Squibb Chart

1 Year Bristol Myers Squibb Chart

1 Month Bristol Myers Squibb Chart

1 Month Bristol Myers Squibb Chart

Your Recent History

Delayed Upgrade Clock